Dementia is a progressive neurodegenerative condition that impairs cognitive function, memory, and daily activities, often requiring complex and evolving medical care. Preventive medications—those prescribed not to treat symptoms but to forestall complications like cardiovascular events, stroke, or diabetes—can accumulate over time, leading to polypharmacy. Polypharmacy, in turn, raises risks of adverse drug reactions, drug interactions, and increased burden on patients and caregivers. Deprescribing, a systematic approach to tapering or stopping medications that may no longer be beneficial or might be harmful, emerges as a critical strategy in geriatric medicine. However, its implementation is fraught with emotional, ethical, and clinical challenges.

The study utilized a qualitative synthesis of multiple prior research efforts, focusing on interviews and discussions with healthcare professionals, including physicians, nurses, and pharmacists, alongside family members intimately involved in caregiving. The researchers isolated themes highlighting the tension between striving to do no harm and the hesitancy to alter long-standing therapeutic regimens. Healthcare professionals often find themselves navigating between clinical guidelines, emerging evidence, and individual patient needs while managing the expectations and fears of family caregivers.

One central revelation from the review was the intricate interplay between clinical decision-making and emotional dynamics. Family members frequently expressed apprehension regarding deprescribing, fearing that stopping preventive medications might hasten decline or cause immediate harm. This anxiety often stems from a limited understanding of medication mechanisms and the progressive nature of dementia itself. Healthcare providers, meanwhile, emphasized the importance of transparent communication and shared decision-making to build trust and alleviate concerns, although they acknowledged time constraints and fragmented healthcare systems as barriers.

Importantly, the research highlighted variations in healthcare providers’ approaches based on their professional roles and experiences. Physicians often focused on medical evidence and risk-benefit analyses, whereas nurses and pharmacists brought forward practical considerations such as medication management complexity and patient adherence. This multidisciplinary perspective underscores the necessity of collaborative care models in optimizing deprescribing protocols and ensuring they align with patients’ goals of care.

The review also sheds light on the ethical dimension embedded in deprescribing preventive medications. Deciding to discontinue a drug that could potentially prevent future ailments requires weighing uncertain benefits against probable risks within a limited life expectancy framework. This places immense responsibility on clinicians to integrate prognosis, patient autonomy, and quality of life considerations while navigating clinical ambiguity. The study advocates for enhanced training in communication skills and ethical reasoning as integral components of deprescribing initiatives.

One of the pivotal technical insights discussed in the review pertains to the pharmacokinetic and pharmacodynamic changes in people with dementia, which can alter drug metabolism and sensitivity. Aging-related renal and hepatic function decline, variations in receptor responsiveness, and the fragility of neural circuits contribute to unpredictable medication effects. Such factors endorse the rationale for periodic medication reviews and adjustment of preventive therapies to minimize adverse outcomes.

Another crucial technical aspect involves the identification of potentially inappropriate medications (PIMs) using validated tools such as the Beers Criteria and STOPP/START criteria. These tools assist clinicians in systematically assessing the risk profiles of medications, especially in polypharmacy contexts typical among elderly patients with dementia. Despite their utility, the review finds that these criteria are underutilized in real-world practice, primarily due to workflow limitations and lack of interdisciplinary coordination.

The role of emerging technologies also features prominently in the discussion. Electronic health records (EHRs) integrated with clinical decision support systems (CDSS) have the potential to flag high-risk medications and suggest deprescribing alternatives. However, clinicians reported limited access to such tools or inconsistent alerts, highlighting a technological gap that warrants attention. Future innovations could include AI-driven predictive analytics tailored to dementia patient cohorts, offering personalized deprescribing strategies.

From a psychosocial perspective, the study elucidates how family caregivers’ cultural background, health literacy, and personal beliefs influence their attitudes toward medication withdrawal. Some caregivers see medications as tangible evidence of active treatment and worry that stopping them might equate to giving up hope. This cultural dimension necessitates the development of tailored educational interventions that respectfully address beliefs and improve understanding of dementia progression and medication impact.

The systematic review also outlines facilitators and barriers to deprescribing. Facilitators included established therapeutic relationships, multidisciplinary team involvement, routine medication reviews, and the use of structured deprescribing protocols. Barriers highlighted were communication gaps, uncertainty about clinical outcomes, limited time during consultations, and the fragmented nature of community and institutional care settings. Addressing these barriers requires health policy reforms, resource allocation, and systemic integration of deprescribing frameworks into routine geriatric care.

Another significant insight relates to the concept of “prescribing inertia,” a phenomenon where medications remain unchanged due to habit, fear of negative outcomes, or lack of updated clinical information. Overcoming this inertia demands proactive engagement from healthcare professionals, supported by continuous education and feedback mechanisms. Encouragingly, some settings reported successful deprescribing outcomes following targeted quality improvement initiatives incorporating multidisciplinary team meetings and patient-centered care planning.

The authors also advocate for enhanced research into biomarkers and clinical indicators that could help predict which patients are likeliest to benefit from deprescribing preventive medications. Such precision medicine approaches could reduce uncertainty and support evidence-based decision-making. Moreover, longitudinal studies tracking cognitive and functional outcomes post-deprescribing are necessary to establish safety profiles and optimize timing and selection of drugs to be tapered.

In conclusion, this rigorous qualitative review underscores the necessity of a holistic, patient-centered approach to deprescribing preventive medication in people living with dementia. It is evident that balancing the risks and benefits of extensive medication regimens requires not only clinical acumen but also empathetic communication and collaboration among healthcare professionals, patients, and families. The study calls for systemic changes to support deprescribing practices, encompassing education, technology, policy, and cultural competence. As dementia prevalence rises worldwide, optimizing medication management through deprescribing will be integral to enhancing the quality of life for millions affected by this challenging condition.

Subject of Research: The perspectives of healthcare professionals and family members on deprescribing preventive medications in people living with dementia.

Article Title: The views of healthcare professionals and family members on deprescribing preventive medication in people living with dementia: a qualitative systematic review.

Article References:
Bates, C., Efstathiou, N., Sutton, C. et al. The views of healthcare professionals and family members on deprescribing preventive medication in people living with dementia: a qualitative systematic review. BMC Geriatr (2026). https://doi.org/10.1186/s12877-026-07480-0

Image Credits: AI Generated

The interpretation of medication management in the elderly focuses on the intricate balance between minimizing adverse drug reactions and ensuring adequate therapeutic effectiveness. As the population ages, the prevalence of polypharmacy — the simultaneous use of multiple medications — increases, often leading to complications that necessitate careful oversight. The STOPP (Screening Tool of Older Persons’ Potentially Inappropriate Prescriptions) and START (Screening Tool to Alert to Right Treatment) criteria serve as tools aimed precisely at this concern, guiding healthcare providers to make informed decisions centered on the best outcomes for elderly patients.

In their recent publication, Boland et al. aim to scrutinize the evidentiary foundation that underpins these widely utilized criteria. The authors delve into the scholarly works that have previously shaped STOPP/START, examining their contributions as well as their limitations. This rigorous analysis is particularly vital given that clinical recommendations must continually adapt in response to evolving research landscapes, especially when addressing the complexities of geriatric patients who often present with multiple comorbidities.

An integral part of their methodology involved a thorough literature review, sifting through peer-reviewed articles and clinical studies that have listed key principles related to medication management in older adults. This extensive review highlighted how existing literature aligns with or diverges from the practical applications of STOPP/START criteria. By identifying gaps in the literature, the researchers aim to pinpoint areas in need of further exploration, which could ultimately lead to an enhancement in the criteria themselves.

One pivotal aspect of the STOPP/START appraisal lies in its emphasis on evidence-based medicine, emphasizing that clinical decisions should be informed by the best available research. This commitment to evidence-based practice is essential, as it lends credibility to the guidelines and helps clinicians make informed, rational decisions about prescribing medications to older patients. The evolving nature of evidence in pharmacology and geriatrics underscores the need for regular updates to established criteria, ensuring that they reflect the most current knowledge and clinical practices.

The implications of these findings are profound; they urge practitioners to be cautious and considerate when prescribing to an aging population. The STOPP/START criteria are structured to prevent potentially inappropriate prescriptions while safeguarding patients against potential therapeutic omissions. This balanced approach is what underpins the importance of continuous research and evaluation — to refine these criteria further and ensure they meet the ever-changing needs of geriatric care.

The research also emphasizes the importance of interdisciplinary collaboration in the management of medications among elderly patients. Gerontologists, pharmacists, and primary care physicians must work closely together to ensure a holistic approach to medication management. This collaborative effort may involve regular reviews of patient medications, comprehensive evaluations of their overall health status, and open dialogues about the benefits and risks associated with their prescribed therapies.

Moreover, the apprehension surrounding polypharmacy is compounded by the fact that older adults often participate in their own medication management, which can introduce variability in adherence and compliance. Through patient education, healthcare providers can empower elderly individuals to understand their treatment plans, leading to improved adherence rates and, consequently, enhanced health outcomes. The STOPP/START criteria serve as a framework that not only guides clinicians but also informs patients about the complexities of their medication regimens.

The researchers acknowledge the broader implications of their appraisal, extending beyond just the academic arena. Policymakers and clinical guidelines could benefit from the insights provided by this critical evaluation. By ensuring that the STOPP/START criteria are both evidence-based and reflective of contemporary practices, there is potential for significant improvements in quality of care. Such enhancements could lead to reduced hospitalizations associated with adverse drug events, lower healthcare costs, and, most importantly, better overall patient health and well-being.

As the findings unfold, the authors encourage further research into the specific patient demographics most impacted by polypharmacy. Understanding particular patterns among different ethnicities, socioeconomic statuses, and health conditions can lead to more tailored and effective interventions. Additionally, the need for randomized controlled trials and further longitudinal studies is emphasized, particularly to assess the long-term outcomes of implementing STOPP/START criteria in clinical settings.

The collaborative nature of this research is commendable, uniting experts with a shared goal of optimizing medication use among elderly patients. Boland and his colleagues represent a collective effort in the scientific community to ensure that clinical practice evolves alongside the burgeoning body of research related to geriatric pharmacotherapy. Their contributions reaffirm the pivotal role of this type of investigative work in shaping the future of patient care.

In summary, the appraisal of the STOPP/START criteria not only reaffirms the necessity for ongoing evaluation of medication management in older adults but also illuminates paths for future research initiatives. By scrutinizing the literature that informs these guidelines, the authors have opened avenues for further inquiry, ultimately aiming to enhance clinical practices that can lead to healthier, happier lives for the elderly population worldwide.

As we look forward to the advancements that will emerge in geriatric medicine, the collective insights gained from this research strive to position healthcare providers to deliver the safest and most effective care to elderly patients grappling with the complexities of multiple medication regimens.

Subject of Research: Appraisal of references supporting the STOPP/START version 3 criteria.

Article Title: Appraisal of the references supporting the STOPP/START.version 3 criteria.

Article References:

Boland, B., Sibille, F.X., Mouzon, A. et al. Appraisal of the references supporting the STOPP/START.version 3 criteria.
Eur Geriatr Med (2025). https://doi.org/10.1007/s41999-025-01386-7

Image Credits: AI Generated

DOI: 10.1007/s41999-025-01386-7

Keywords: geriatrics, STOPP, START, polypharmacy, medication management, evidence-based medicine, elderly care, clinical practice, healthcare collaboration.

Medication management for older adults is increasingly recognized as a nuanced domain that necessitates specialized knowledge. As individuals age, they often experience multiple comorbidities that require careful consideration when it comes to pharmacotherapy. The research team, comprising experts from various fields of geriatric care, has created a comprehensive PIPC list that serves as a guideline for clinicians. This list is designed to help practitioners avoid well-documented pitfalls that can arise from prescribing cascades, wherein the introduction of a new medication can lead to a series of complex interrelated drug administrations that may not only fail to provide therapeutic benefit but also result in potential harm.

Underlining their findings, the researchers emphasize that the PIPC list is not merely a set of recommendations; it represents an evolving body of evidence-based insights that can adapt to ongoing research and clinical experiences. This adaptability is crucial in an era where clinical guidelines often lag behind emerging data. By utilizing the PIPC framework, healthcare providers can engage in shared decision-making with their patients, allowing for a more personalized approach to treatment that takes into consideration individual preferences and specific health needs.

The implications of inappropriate prescribing are far-reaching, particularly within the geriatric population. As older adults frequently present with polypharmacy—a situation where multiple medications are prescribed—the risk of adverse drug reactions escalates significantly. These reactions can lead to hospitalizations, increased morbidity, and even mortality. The PIPC list serves as a proactive tool for clinicians to mitigate these risks, creating a safety net that can potentially safeguard vulnerable populations who are often at the mercy of their medication regimens.

In the context of clinical practice, the expert panel’s findings advocate for ongoing education and training in geriatric pharmacotherapy. Healthcare professionals must remain vigilant and aware of the evolving nature of drug interactions, side effects, and the specific needs of older adults. By fostering a culture of learning and inquiry, medical practitioners can be better equipped to navigate the complexities of prescribing, ultimately enhancing patient outcomes and quality of care.

Another essential aspect of the panel’s research is the emphasis on interdisciplinary collaboration. Geriatric medicine inherently involves a multi-faceted approach, which requires cooperation between various healthcare providers, including physicians, pharmacists, nurses, and allied health professionals. The active involvement of these diverse specialists enhances the understanding of each patient’s unique situation, promoting comprehensive care that addresses both medical and social determinants of health. The PIPC list introduces a platform for dialogue among interdisciplinary teams, ensuring that all perspectives are considered before a treatment plan is finalized.

Moreover, the prevalence of health literacy plays a crucial role in the effectiveness of prescribing practices. The research highlights the necessity for healthcare providers to engage in clear, open communication with patients regarding their treatment options. When patients are well-informed, they are more likely to adhere to prescribed regimens, understand the rationale behind their medications, and participate actively in their own health management. The PIPC framework encourages this dialogue, reinforcing the idea that medication discussions should involve patients as key stakeholders in their treatment decisions.

The phenomenon of medication adherence—or lack thereof—poses significant challenges within the geriatric population. The consequences of non-adherence can range from suboptimal health outcomes to preventable hospital admissions. By incorporating the PIPC list into routine clinical practice, healthcare professionals can address barriers to adherence, such as cognitive decline or complex regimens. The framework allows for a more streamlined approach to medication management that takes into account each patient’s capacity to comply with prescribed therapies.

In expanding the conversation around the PIPC list, it is essential to acknowledge the importance of continuous research in this area. The landscape of medicine is in constant flux, with new medications and therapies being introduced regularly. Keeping abreast of these developments is not just beneficial; it is imperative for practitioners who aim to deliver safe and effective care to their patients. The expert panel calls for future studies to validate and refine the PIPC list, ensuring it remains relevant and effective in a rapidly changing healthcare environment.

As healthcare evolves, so does the responsibility of clinicians to refine their practice continuously. The PIPC list serves as a beacon for physicians and healthcare professionals striving for excellence, reminding them that vigilance and continuous education are paramount in the quest to improve patient care. By embracing the findings of this study, healthcare workers can contribute to a future where the risks associated with inappropriate prescribing are significantly minimized, allowing geriatric patients to enjoy healthier, more fulfilling lives.

In summary, the international expert panel’s work in developing the potentially inappropriate prescribing cascades (PIPC) list underscores a pivotal moment in understanding how to improve prescribing practices for older adults. This innovative resource provides healthcare professionals with a structured approach to evaluate and rethink their prescribing habits. As the research gains traction in medical communities worldwide, it holds the potential to transform the landscape of geriatric pharmacotherapy for years to come.

The findings presented in this study are not merely an academic exercise; they represent a call to action for healthcare professionals to reassess how they approach medication management for older patients. By adopting the principles outlined in the PIPC list, clinicians can work towards reducing the prevalence of adverse drug reactions in the geriatric population, ultimately paving the way for safer, more effective healthcare delivery.

Subject of Research: Potentially inappropriate prescribing cascades in geriatric medicine.

Article Title: International expert panel’s potentially inappropriate prescribing cascades (PIPC) list.

Article References:

Rochon, P.A., O’Mahony, D., Cherubini, A. et al. International expert panel’s potentially inappropriate prescribing cascades (PIPC) list. Eur Geriatr Med (2025). https://doi.org/10.1007/s41999-025-01215-x

Image Credits: AI Generated

DOI:

Keywords: Potentially inappropriate prescribing, geriatric medicine, pharmacotherapy, patient safety, medication management.